The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy.
In a search for a pharmacologic adjuvant in the management of posttraumatic proliferative vitreoretinopathy (PVR), we investigated the effect of intravitreal injection of prinomastat (AG3340) on an experimental model. Posterior penetrating eye trauma was created in one eye each of 24 New Zealand white rabbits. One week after the surgery, all rabbits were randomized (1:1) to receive 0.5 mg prinomastat or the vehicle of the drug intravitreally every week for 6 weeks. The degree of PVR for each hemiretina was scored, and the two scores were summed to obtain a total eye score. The mean total eye score was 3.58 in the treatment group and 5.75 in the control group (p = 0.0307). The numbers of eyes with tractional retinal detachment in the prinomastat-treated (n = 12) and control (n = 12) groups were 3 and 9, respectively (p = 0.0391). These results suggest that intravitreally administered prinomastat has an inhibitory effect on posttraumatic PVR.
Ozerdem
U
U
Shiley Eye Center, University of California, San Diego, CA 92093-0946, USA.
Mach-Hofacre
B
B
Keefe
K
K
Pham
T
T
Soules
K
K
Appelt
K
K
Freeman
W R
WR
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D015807:Eye Injuries, Penetrating / Q000150:complications* / Q000473:pathology; D005260:Female; D007267:Injections; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009930:Organic Chemicals; D011817:Rabbits; D012160:Retina / Q000187:drug effects / Q000293:injuries*; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D014822:Vitreous Body / Q000187:drug effects / Q000293:injuries*
D000970:Antineoplastic Agents; D009930:Organic Chemicals; C113282:prinomastat; D008666:Metalloendopeptidases